Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01985360 · ClinicalTrials.gov registry record · Phase 4
ISCHEMIA-Chronic Kidney Disease Trial
A Phase 4 study of Cardiovascular Diseases and Coronary Artery Disease, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 777
- Enrollment target
- 1
- Study location
NCT01985360 is a Phase 4 study of Cardiovascular Diseases and Coronary Artery Disease that has completed, run by NYU Langone Health. The registered enrollment target is 777 participants, below the 26,972-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01985360, a Phase 4 study of Cardiovascular Diseases and Coronary Artery Disease, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 777 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the ISCHEMIA-CKD trial is to determine the best management strategy for patients with stable ischemic heart disease (SIHD), at least moderate inducible ischemia and advanced chronic kidney disease (CKD; estimated glomerular filtration rate \[eGFR\] \<30 ml/min/1.73 m² or on dialysis). This is a multicenter randomized controlled trial of 777 randomized participants with advanced CKD. Participants were assigned at random to a routine invasive strategy (INV) with cardiac catheterization (cath) followed by revascularization (if suitable) plus optimal medical therapy (OMT) or to a conservative strategy (CON) of OMT, with cath and revascularization reserved for those who fail OMT. The trial is designed to run seamlessly in parallel to the main ISCHEMIA trial as a companion trial. SPECIFIC AIMS A. Primary Aim. The primary aim of the ISCHEMIA-CKD trial is to determine whether an invasive strategy of cardiac cath followed by optimal revascularization, in addition to OMT, will reduce the primary composite endpoint of death or nonfatal myocardial infarction in participants with SIHD and advanced CKD over an average follow-up of approximately 2.8 years compared with an initial conservative strategy of OMT alone with catheterization reserved for those who fail OMT. The primary endpoint is time to centrally adjudicated death or nonfatal myocardial infarction (MI). B. Secondary Aims. Major: To compare the incident of the composite of death, nonfatal MI, resuscitated cardiac arrest, or hospitalization for unstable angina or heart failure, and angina symptoms and quality of life, as assessed by the Seattle Angina Questionnaire, between the INV and CON strategies. Other secondary aims include: comparing the incidence of the composite of death, nonfatal MI, hospitalization for unstable angina, hospitalization for heart failure, resuscitated cardiac arrest, or stroke; composite of death, nonfatal MI, or stroke; composite endpoints incorporating cardiovascular death; c
Conditions Studied
Interventions
- PROCEDURE Cardiac Catheterization
- BEHAVIORAL Lifestyle
- DRUG Medication
- PROCEDURE Coronary Artery Bypass Graft Surgery
- PROCEDURE Percutaneous Coronary Intervention
Study Locations (1)
New York
- NYU Langone Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 777 participants |
| Start Date | 2014-01 |
| Est. Completion | 2020-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01985360
The ClinicalTrials.gov registry entry for NCT01985360 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 777 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,972-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (97% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 5 interventions - of which Cardiac Catheterization is the first listed.
NCT01985360 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01985360 about?
NCT01985360 is a clinical study titled "ISCHEMIA-Chronic Kidney Disease Trial". The purpose of the ISCHEMIA-CKD trial is to determine the best management strategy for patients with stable ischemic heart disease (SIHD), at least moderate inducible ischemia and advanced chronic kidney disease (CKD; estimated glomerular filtration rate \[eGFR\] \<30 ml/min/1.73 m² or on dialysis)....
What is the current status of trial NCT01985360?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 777 participants. The study started on 2014-01. Estimated completion is 2020-07.
What conditions does trial NCT01985360 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia, Kidney Disease.
What interventions are being tested in trial NCT01985360?
The interventions under investigation include: Cardiac Catheterization (PROCEDURE), Lifestyle (BEHAVIORAL), Medication (DRUG), Coronary Artery Bypass Graft Surgery (PROCEDURE), Percutaneous Coronary Intervention (PROCEDURE).
Who is sponsoring clinical trial NCT01985360?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01985360 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
RECRUITING · Phase 4
-
NSAIDs vs. Coxibs in the Presence of Aspirin
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.